AUTHORS
Giancarlo Castaman, MD, Antonio Coppola2, Gaetano Giuffrida3, Flora Peyvandi4, Cristina Santoro5, Michele Schiavulli6, Sergio Siragusa, MD7, Ezio Zanon8, Enrico Ferri Grazzi9, Paolo Angelo Cortesi10, Sara Bendinelli11, Michela Chinelli12, Raffaella Perrone13, Matteo Nicola Dario Di Minno, MD, PhD14
AFFILIATIONS
1 Department of Oncology, Centre for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy
2 SSD Centro Hub Emofilia e Malattie Emorragiche Congenite Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
3 Azienda Ospedaliero Universitaria Policlinico 'G.Rodolico-San Marco', Catania, Italy
4 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
5 Hematology, University Hospital Policlinico Umberto I, Rome, Italy
6 UOSD Centro Regionale Pediatrico malattie della coagulazione, Naples, Italy
7 U.O. di Ematologia Azienda Ospedaliera Universitaria Policlinico 'Paolo Giaccone', Palermo, Italy
8 Centro Emofilia, Clinica Medica 1° azienda ospedale Università di Padova, Padua, Italy
9 Federation of Haemophilia Associations (FedEmo), Milan, Italy
10 Research Centre on Public Health (CESP), University of Milano-Bicocca, Monza, Italy
11 Roche S.p.A. Italy, Monza, Italy
12 Roche S.p.A. Italy, Monza, Italy
13 Roche S.p.A. Italy, Monza, Italy
14 Department of Clinical Medicine and Surgery, Regional Reference Center for Coagulation Disorders, Federico II University, Naples, Italy
ABSTRACT
Introduction
Advances in hemophilia A (HA) treatment have led to lower bleeding rates, shifting focus toward endpoints such as joint health and HRQoL. Comprehensive assessment of the value of care in HA requires multidimensional outcome indicators capturing patient-reported health status. Traditional indicators often fail to fully reflect patients’ perspectives in the evolving treatment landscape, like in recent years the introduction of the first non-replacement therapy [Manco-Johnson MJ et al., Haemophilia. 2021]. The HemPROve study evaluated in a real-world setting a novel composite Patient-Reported Outcome Indicator (PROI), developed within a value-based healthcare framework, integrating pain and functional domains in adults and children/teenagers [Cortesi PA et al., Haemophilia. 2024].
Methods
HemPROve was an Italian, multicenter, non-interventional, cross-sectional study evaluating patients aged ≥6 years with severe HA without inhibitors treated with a prophylaxis therapy approved at time of study start. Data was collected at a single time point. The composite Patient-Reported Outcomes Index (PROI; utility score 0–10) was derived by merging the Brief Pain Inventory Short Form (BPI-SF) [Cleeland CS. The Brief Pain Inventory User Guide. 2009] and the Haemophilia Activities List (HAL/PedHAL) [van Genderen FR, et al. Haemophilia. 2006; Groen WG et al., Haemophilia. 2010] into age-adjusted health states reflecting pain, mobility, and daily physical activity. Descriptive and multivariable regression analyses explored PROI score distribution and its associations with the following characteristics: age, education, comorbidities requiring treatment, Haemophilia Joint Health Score (HJHS), prophylaxis type (including frequency and duration), and the number of bleeds in the prior 24 weeks.
Results
Out of 128 patients enrolled across 13 Italian clinical centers, 120 were evaluable for the primary analysis according to the following age groups: 6–13 years, n=30 (25.0%); 14–35 years, n=39 (32.5%); 36–65 years, n=41 (34.2%); >65 years, n=10 (8.3%). At enrolment, non-replacement therapy (n=55, 45.8%) and extended half-life (EHL) FVIII replacement therapies (n=53, 44.2%) were most used, while standard half-life (SHL) FVIII replacement therapies accounted for 10% (n=12) of patients. Overall, prophylaxis was administered at a high-medium frequency (i.e. more than once weekly) in 52.5% (n=63) of cases, and at a low frequency (i.e. once weekly or less) in 47.5% (n=57). The ongoing prophylactic regimen had been maintained for a median of 50.6 months (interquartile range 25.1–66.9). The distribution of the composite PROI showed that n=58 (48.3%) patients were classified in the best health state, defined by mean BPI-SF pain severity and pain interference score levels of 0-3 and a HAL/PedHAL normalized score level ≥90, with progressively lower proportions across less favorable states. Utility score demonstrated a high overall level of patient-reported health status (mean 7.9, standard deviation 2.2), with n=58 (48.3%) patients achieving the maximum score (10). In multivariable analysis, higher number of treated bleeds in the previous 24 weeks was strongly associated with worse PROI scores (estimate=−0.903; p=0.0003). Increasing age was also associated with lower utility scores (estimate=−0.048; p=0.0012), whereas longer duration of prophylaxis (in months) was associated with improved outcomes (estimate=+0.008; p=0.0292). HJHS being assessed in n=66 (55.0%) patients, and higher HJHS total scores were significantly associated with lower utility scores. No significant associations were observed for educational level or comorbidity status. The model explained a substantial proportion of variability in PROI (R²=0.41).
Conclusion
In patients with severe HA without inhibitors on prophylaxis, mainly with non-replacement or EHL FVIII therapies, patient-reported health status is generally high. However, an older age and a higher bleeding burden are independent predictors of worse patient-reported health, whereas longer prophylaxis exposure correlates with improved outcomes. These primary findings highlight the potential value of the composite PROI in clinical practice. The ongoing secondary endpoints analyses will further characterize the distribution of this composite index, and its specific components across different age groups, correlating them with clinical and educational factors.
This study was sponsored and financially supported by Roche S.p.A.
DISCLOSURES
Cristina Santoro: No relevant conflicts of interest to declare.